About Us

Our Story

We believe in the power of innovation and collaboration to drive success. From humble beginnings as a small team with big dreams, we have grown into a therapeutics development company committed to creating treatments for challenging diseases.
Our mission is clear: to deliver impactful results through innovative strategies, efficient small molecule synthesis technology, and an unwavering passion for advancing therapeutics.

Our team of experts values originality, differentiated approaches, and a steadfast commitment to improving patient care. We take pride in achieving best-in-class results that consistently exceed expectations. Every project we undertake reflects our dedication to enhancing patients’ quality of life and pushing the boundaries of what’s possible in therapeutics development.

Key Executives

CEO

Lim Sang Myoun

CEO Lim Sang Myoun

• 2022 Amenis Bioscience , Inc., CEO

• 2019 Anenti Therapeutics Co., Ltd., CEO

• 2019 Yuhan Corporation, Central R&D Center

• 2011 Genotech Co., Ltd., R&D Center

• 2006 Korea Research Institute of Bioscience and Biotechnology

• 2003 Kogen Biotech Co., Ltd.

• 2000 Sungkyunkwan University (BS/MS)

CSO

Jeffrey Encinas

CSO Jeffrey Encinas

• 2022 Amenis Bioscience , Inc., Co-Founder

• 2019 Anenti Therapeutics, Co-Founder

• 2018 Sanofi, Asia-Pacific Innovation Center

• 2013 Novartis, Japan

• 2006 Boehringer Ingelheim, Japan

• 1999 Bayer Yakuhin, Japan

• 1997 Harvard University (MS/Ph.D)

• 1985 UC Berkeley, Molecular Biology (B.S.)

Collaborative Research Team

We have been continuously collaborating with Japanese universities that have been researching the relationship between Pin1 function and diseases for over 15 years, while also studying the structural chemistry of small-molecule compounds.